Update in Endocrinology: Evidence Published in 2010
Authors: Anthony DeSantis
Journal: Annals of Internal Medicine (2011)

Updates17 May 2011Update in Endocrinology: Evidence Published in 2010Anthony DeSantis, MDAnthony DeSantis, MDFrom University of Washington, Seattle, Washington.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-154-10-201105170-00340 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail This update reviews articles on endocrinology published in the top peer-reviewed medical journals in 2010. Those articles that had high-quality design and led to conclusions with important clinical applicability for general internists.Calcium and Bone MetabolismRetrospective Analysis of Bisphosphonate Exposure and Atypical Fracture Risk Black DM , Kelly MP , ...References1. Lenart BA, Lorich DG, Lane JM. Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate [Letter]. N Engl J Med. 2008;358:1304-6. [PMID: 18354114] CrossrefMedlineGoogle Scholar2. Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA. 1998;280:2077-82. [PMID: 9875874] CrossrefMedlineGoogle Scholar3. Black DM, Schwartz AV, Ensrud KE, Cauley JA, Levis S, Quandt SA, et al; FLEX Research Group. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA. 2006;296:2927-38. [PMID: 17190893] CrossrefMedlineGoogle Scholar4. Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, et al; HORIZON Pivotal Fracture Trial. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007;356:1809-22. [PMID: 17476007] CrossrefMedlineGoogle Scholar5. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care. 1993;16:434-44. [PMID: 8432214] CrossrefMedlineGoogle Scholar6. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998;317:703-13. [PMID: 9732337] CrossrefMedlineGoogle Scholar7. Hansson L, Zanchetti A, Carruthers SG, Dahl f B, Elmfeldt D, Julius S, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet. 1998;351:1755-62. [PMID: 9635947] CrossrefMedlineGoogle Scholar8. National Diabetes Information Clearinghouse. Diabetes Statistics–Complications of Diabetes. Accessed at www.niddk.nih.gov/health/diabetes/pubs/dmstats/dmstats.htm. on 9 August 2006. Google Scholar9. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-9. [PMID: 7968073] MedlineGoogle Scholar10. Rubins HB, Robins SJ, Collins D, Nelson DB, Elam MB, Schaefer EJ, et al. Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT). Arch Intern Med. 2002;162:2597-604. [PMID: 12456232] CrossrefMedlineGoogle Scholar11. Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, et al; FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005;366:1849-61. [PMID: 16310551] CrossrefMedlineGoogle Scholar12. Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P, et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med. 1987;317:1237-45. [PMID: 3313041] CrossrefMedlineGoogle Scholar13. Gerstein HC, Miller ME, Byington RP, Goff DC, Bigger JT, Buse JB, et al; Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545-59. [PMID: 18539917] CrossrefMedlineGoogle Scholar14. Cushman WC, Evans GW, Byington RP, Goff DC, Grimm RH, Cutler JA, et al; ACCORD Study Group. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010;362:1575-85. [PMID: 20228401] CrossrefMedlineGoogle Scholar15. Ginsberg HN, Elam MB, Lovato LC, Crouse JR, Leiter LA, Linz P, et al; ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362:1563-74. [PMID: 20228404] CrossrefMedlineGoogle Scholar16. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352:837-53. [PMID: 9742976] CrossrefMedlineGoogle Scholar17. Haslam DW, James WP. Obesity. Lancet. 2005;366:1197-209. [PMID: 16198769] CrossrefMedlineGoogle Scholar18. Goldstein DJ. Beneficial health effects of modest weight loss. Int J Obes Relat Metab Disord. 1992;16:397-415. [PMID: 1322866] MedlineGoogle Scholar19. Greenway FL, Dunayevich E, Tollefson G, Erickson J, Guttadauria M, Fujioka K, et al; NB-201 Study Group. Comparison of combined bupropion and naltrexone therapy for obesity with monotherapy and placebo. J Clin Endocrinol Metab. 2009;94:4898-906. [PMID: 19846734] CrossrefMedlineGoogle Scholar20. Whitlock G, Lewington S, Sherliker P, Clarke R, Emberson J, Halsey J, et al; Prospective Studies Collaboration. Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. Lancet. 2009;373:1083-96. [PMID: 19299006] CrossrefMedlineGoogle Scholar21. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393-403. [PMID: 11832527] CrossrefMedlineGoogle Scholar22. Wing RR, Hill JO. Successful weight loss maintenance. Annu Rev Nutr. 2001;21:323-41. [PMID: 11375440] CrossrefMedlineGoogle Scholar23. Rothman RB, Baumann MH. Appetite suppressants, cardiac valve disease and combination pharmacotherapy. Am J Ther. 2009;16:354-64. [PMID: 19092640] CrossrefMedlineGoogle Scholar24. Feldman HA, Longcope C, Derby CA, Johannes CB, Araujo AB, Coviello AD, et al. Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts male aging study. J Clin Endocrinol Metab. 2002;87:589-98. [PMID: 11836290] CrossrefMedlineGoogle Scholar25. Harman SM, Metter EJ, Tobin JD, Pearson J, Blackman MR; Baltimore Longitudinal Study of Aging. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab. 2001;86:724-31. [PMID: 11158037] CrossrefMedlineGoogle Scholar26. Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, Swerdloff RS, et al; Task Force Endocrine Society. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2010;95:2536-59. [PMID: 20525905] CrossrefMedlineGoogle Scholar27. Newman AB, Simonsick EM, Naydeck BL, Boudreau RM, Kritchevsky SB, Nevitt MC, et al. Association of long-distance corridor walk performance with mortality, cardiovascular disease, mobility limitation, and disability. JAMA. 2006;295:2018-26. [PMID: 16670410] CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: From University of Washington, Seattle, Washington.Article relevant to primary care general internistsArticle relevant to hospitalistsDisclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M11-0252.Corresponding Author: Anthony DeSantis, MD, University of Washington, Division of Metabolism, Endocrinology, and Nutrition, 4225 Roosevelt Avenue Northeast, Suite 101, Seattle, WA 98105; e-mail, [email protected]washington.edu.Author Contributions: Conception and design: A. DeSantis.Analysis and interpretation of the data: A. DeSantis.Drafting of the article: A. DeSantis.Critical revision for important intellectual content: A. DeSantis.Final approval of the article: A. DeSantis.Collection and assembly of data: A. DeSantis. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 17 May 2011Volume 154, Issue 10Page: 684-689KeywordsBlood pressureDrugsHypogonadismMedical risk factorsMyocardial infarctionObesityTestosteroneThyroxineType 2 diabetesWeight loss ePublished: 17 May 2011 Issue Published: 17 May 2011 CopyrightCopyright © 2011 by American College of Physicians. All Rights Reserved.PDF DownloadLoading ...